2021
Cancer-related fatigue—pharmacological interventions: systematic review and network meta-analysis
Chow R, Bruera E, Sanatani M, Chiu L, Prsic E, Boldt G, Lock M. Cancer-related fatigue—pharmacological interventions: systematic review and network meta-analysis. BMJ Supportive & Palliative Care 2021, 13: 274-280. PMID: 34593386, DOI: 10.1136/bmjspcare-2021-003244.Peer-Reviewed Original ResearchConceptsCancer-related fatiguePharmacologic interventionsSystematic reviewCochrane Central RegisterFuture clinical trialsMore safety dataCentral RegisterHead trialsControlled TrialsCommon symptomsFuture trialsClinical trialsSafety dataDirect headMean differenceParoxetineModafinilTrialsInterventionPatientsCancer researchReviewPlaceboEMBASEMEDLINEA Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
Herbst R, Jassem J, Abogunrin S, James D, McCool R, Belleli R, Giaccone G, De Marinis F. A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. Frontiers In Oncology 2021, 11: 676732. PMID: 34307144, PMCID: PMC8300186, DOI: 10.3389/fonc.2021.676732.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalObjective response rateStage IV non-small cell lung cancerFirst-line treatmentOverall survivalCell lung cancerLung cancerHigh Programmed-Death Ligand 1 (PD-L1) expressionMetastatic non-small cell lung cancerStage non-small cell lung cancerProgrammed Death Ligand 1 ExpressionTreatment-related adverse eventsDeath ligand 1 (PD-L1) expressionPD-L1 expressionPD-L1 statusAbsence of headNetwork Meta-AnalysisRisk of biasRandom-effects modelVersus ChemotherapyImmunotherapy regimenAdverse eventsHead trialsCombination regimens
2020
Pharmacologic and surgical therapies for patients with Meniere’s disease: A systematic review and network meta-analysis
Ahmadzai N, Cheng W, Kilty S, Esmaeilisaraji L, Wolfe D, Bonaparte J, Schramm D, Fitzpatrick E, Lin V, Skidmore B, Hutton B. Pharmacologic and surgical therapies for patients with Meniere’s disease: A systematic review and network meta-analysis. PLOS ONE 2020, 15: e0237523. PMID: 32870918, PMCID: PMC7462264, DOI: 10.1371/journal.pone.0237523.Peer-Reviewed Original ResearchConceptsComplete vertigo controlEndolymphatic sac decompressionRandomized clinical trialsEndolymphatic duct blockageIT steroidsVertigo controlMeniere's diseaseIT gentamicinSurgical interventionSystematic reviewKey patient outcomesHigh cumulative dosageBest treatment optionSensorineural hearing lossEDB groupESD groupAural fullnessIntratympanic gentamicinSteroid injectionVertigo attacksHead trialsHearing preservationSurgical therapyCochrane LibraryCumulative dosageDeep Brain Stimulation Target Selection in Co-Morbid Essential Tremor and Parkinson’s Disease
Wadhwa A, Schaefer S, Gerrard J, Deeb W, Okun MS, Patel A. Deep Brain Stimulation Target Selection in Co-Morbid Essential Tremor and Parkinson’s Disease. Tremor And Other Hyperkinetic Movements 2020, 10: 17. PMID: 32775031, PMCID: PMC7394224, DOI: 10.5334/tohm.62.Peer-Reviewed Original ResearchConceptsDeep brain stimulationParkinson's diseaseEssential tremorHead trialsDBS targetsAction tremorSubthalamic nucleus (STN) DBSThalamus deep brain stimulationLimited evidenceDBS target selectionVentral intermediate nucleusBilateral STNPD patientsDBS treatmentEquivalent efficacyRest tremorMild improvementCurrent evidenceET patientsET tremorBrain stimulationComparative efficacyPatientsExpert consensusTremor reductionPharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review.
Artukoglu BB, Li F, Szejko N, Bloch MH. Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32459404, DOI: 10.4088/jcp.19r12798.Peer-Reviewed Original ResearchConceptsTreatment of TDGreater score reductionPlacebo-controlled trialTardive dyskinesiaVitamin EPharmacologic treatmentTD symptomsScore reductionSystematic reviewPublication biasVesicular monoamine transporter 2 (VMAT2) inhibitorTardive dyskinesia treatmentVitamin E studiesTransporter 2 inhibitorsCalcium channel blockersDuration of treatmentTardive dyskinesia symptomsGreater reductionFixed-effects modelMedication classesHead trialsDyskinesia symptomsPrimary outcomePharmacologic agentsVMAT2 inhibitors
2017
Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis.
Stuckelman ZD, Mulqueen JM, Ferracioli-Oda E, Cohen SC, Coughlin CG, Leckman JF, Bloch MH. Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis. The Journal Of Clinical Psychiatry 2017, 78: e648-e655. PMID: 28682529, DOI: 10.4088/jcp.15r10601.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderRisk of irritabilitySide effectsPsychostimulant medicationPsychostimulant treatmentAmphetamine derivativesPlacebo-controlled trialCommon side effectsStratified subgroup analysisEffects of amphetamineTreatment of childrenDuration of usePsychostimulant classesEligible trialsMedical comorbiditiesHead trialsSubgroup analysisRisk ratioRelative riskSTUDY SELECTIONEffective treatmentData sourcesPubMed searchTrial designStimulant type
2010
Clinical Differences Between Solifenacin and Tolterodine
Mongiu A, Lerner L. Clinical Differences Between Solifenacin and Tolterodine. Current Bladder Dysfunction Reports 2010, 6: 1-6. DOI: 10.1007/s11884-010-0075-2.Peer-Reviewed Original ResearchOveractive bladderClinical efficacyDry mouthSide effectsTreatment of OABBothersome urinary symptomsTolerable side effectsMainstay of treatmentGood clinical efficacyInvoluntary detrusor contractionsGood clinical resultsSimilar side effectsAntimuscarinic therapyUrinary symptomsDetrusor contractionHead trialsOAB treatmentClinical differencesClinical resultsPubMed reviewUS prevalenceBetter outcomesSolifenacinTolterodineStudy participantsRole of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.
Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Research 2010, 30: 2927-33. PMID: 20683034.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCapecitabineDeoxycytidineDose-Response Relationship, DrugEpirubicinFemaleFluorouracilgamma-Aminobutyric AcidGastrointestinal NeoplasmsGemcitabineHumansMaleMiddle AgedNeurotoxicity SyndromesOrganoplatinum CompoundsOxaliplatinPregabalinConceptsSensory neuropathyTarget doseLow dosesDose-related side effectsEfficacy of pregabalinOxaliplatin-induced neurotoxicityRole of pregabalinMajority of patientsGastrointestinal cancer patientsOnset of benefitGastrointestinal malignanciesHead trialsNeurological symptomsOxaliplatin useCancer patientsSide effectsPregabalinGrade 2PatientsNeuropathyNeurotoxicityDoseDosesEfficacyTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply